Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE015 (POL) (Dr. Ito)
· consented 2023-03-18
Adverse events
5
Serious AEs
2
Open data queries
0
Luna dropout signal
–
Adverse events
severe
serious
assessed
2026-08-18
Grade 4 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-04-11 (study day 10); relationship: N; serious criteria: life-threatening
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-10 (study day 39); relationship: N
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-08-22 (study day 509); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-08-29 (study day 516); relationship: not assessed; serious criteria: hospitalization
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-12-10 (study day 619); relationship: Y
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.